がん患者の心臓を守る！　腫瘍循環器学Q&A

出版社： 文光堂
著者：
発行日： 2018-03-16
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619434
電子書籍版： 2018-03-16 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

商品紹介

がん治療の進歩により，がん患者の生存率が大幅に改善され，さらに新しいがん治療法も次々と生み出されている一方で，がんサバイバーの心血管疾患による死亡や，がん治療による心毒性が話題となっている．これらの問題に取り組む新たな学際領域として「腫瘍循環器学(Onco-Cardiology/Cardio-Oncology)」が生まれた．本邦ではまだ数少ないエキスパートの先生方に主要なテーマをQ&A方式で執筆して頂き，1テーマ見開き2ページの簡潔なスタイルでまとめた．

目次

  • Part １　腫瘍循環器とは
    　Q1 腫瘍循環器（Onco-CardiologyあるいはCardio-Oncology）とはどういうものでしょうか？
    　Q2 腫瘍循環器外来とはどのようなものでしょうか？ その役割を教えてください
    　Q3 最近のがん治療の進歩により，がん患者の生命予後はどの程度改善されたのでしょうか？
    　Q4 がん治療における心血管副作用にはどのようなものがあるか教えてください
    　Q5 放射線治療による心血管合併症について教えてください
    　Q6 腫瘍循環器医と腫瘍医の協力体制をどのように構築すべきか教えてください
    　Q7 がんサバイバーの定義とその長期予後に対する心血管疾患の影響を教えてください
    　Q8 成人になった小児がん患者の心血管リスクについて教えてください
    　Q9 高齢がん患者へのがん治療における心血管合併症について教えてください
    　Q10 欧米におけるOnco-Cardiologyへの取り組みを教えてください

    Part ２　がん治療に伴う心毒性
    2‒1 心毒性の診断
    　Q11 心毒性（心血管合併症）はどのように分類されますか？
    　　　　どの治療で心毒性が出現するのでしょうか？
    　Q12 Cancer therapeutics-related cardiac dysfunction（CTRCD）はどのようなものでしょうか？
    　　　　その臨床的意義を教えてください
    　Q13 がん治療前にするべき循環器検査があれば教えてください
    　Q14 がん治療による心毒性をどのように診断したらよいのでしょうか？：
    　　　　バイオマーカー，心電図
    　Q15 がん治療による心毒性をどのように診断したらよいのでしょうか？：画像診断
    2‒2 がん治療と心機能障害／心不全
    　Q16 アントラサイクリン系薬はどのようなものでしょうか？
    　　　　作用機序，適応となるがんについて教えてください
    　Q17 アントラサイクリン系薬による心不全の頻度と特徴，ハイリスク患者について教えてください
    　Q18 アントラサイクリン系薬による心毒性のメカニズムを教えてください
    　Q19 HER2阻害薬はどのようなものでしょうか？ また，適応となるがんについて教えてください
    　Q20 HER2阻害薬による心毒性の特徴と頻度，そしてその機序を教えてください
    　Q21 抗VEGF薬はどのようなものでしょうか？ また，適応となるがんについて教えてください
    　Q22 抗VEGF薬による心毒性の特徴と頻度，そしてその機序を教えてください
    　Q23 チロシンキナーゼ阻害薬はどのようなものでしょうか？
    　　　また，適応となるがんについて教えてください
    　Q24 チロシンキナーゼ阻害薬による心毒性の特徴と頻度，そしてその機序を教えてください
    　Q25 プロテアソーム阻害薬の作用機序，適応となるがんとその心毒性について教えてください
    　Q26 免疫チェックポイント阻害薬（抗PD-1抗体）の作用機序，
    　　　　適応となるがんとその心毒性について教えてください
    　Q27 胸部への放射線療法による心機能障害と弁膜症，そして心膜炎について教えてください
    　Q28 抗がん剤による心毒性が認められたら，どのように対処したらよいでしょうか？
    　Q29 抗がん剤の心毒性に対する予防法があれば教えてください
    　Q30 抗がん剤には晩発性心筋障害もあると聞きました．
    　　　　慢性期の心機能チェックと治療はどのようにすればよいでしょうか？
    2‒3 がん治療と血管障害
    　Q31 がん治療が動脈硬化を促進し，心血管イベントを増加させることがあるのでしょうか？
    　Q32 抗がん剤（フルオロピリミジン，シスプラチン，抗VEGF薬）による
    　　　　血管障害とその機序を教えてください
    　Q33 がん治療に伴う血管障害や冠動脈疾患を診断する方法について教えてください
    　Q34 抗がん剤による高血圧はどのように起こるのでしょうか？
    　　　　注意すべき薬剤とその機序について教えてください
    　Q35 抗がん剤による高血圧の薬物治療について教えてください
    　Q36 抗がん剤による腎機能障害はどのように起こるのでしょうか？
    　　　　注意すべき薬剤とその機序について教えてください
    　Q37 がんあるいは抗がん剤による肺高血圧症について教えてください
    　Q38 どのような患者で冠動脈イベントや血管障害に気をつけなければいけないのでしょうか？
    　Q39 がん患者の冠動脈疾患の治療と予防，そして注意点を教えてください
    　Q40 胸部への放射線療法により惹起される冠動脈疾患に特徴はありますか？
    　　　　その対策を教えてください
    2‒4 がん治療と不整脈
    　Q41 抗がん剤に関連する不整脈について教えてください
    　Q42 抗がん剤によるQT延長とその臨床的意義を教えてください
    　Q43 がん患者には心房細動が多いと聞きました．本当でしょうか？
    　Q44 がん患者の心房細動に対して抗凝固療法をどのようにしたらよいでしょうか？

    Part ３　クローズアップされるがん関連血栓塞栓症
    　Q45 がん関連血栓塞栓症（CAT）の機序について教えてください
    　Q46 がん患者の動脈血栓塞栓症の頻度とその機序について教えてください
    　Q47 がん患者の静脈血栓塞栓症（VTE）とその臨床的重要性について教えてください
    　Q48 どのようながん患者がVTEのハイリスクなのでしょうか？
    　　　　その予測スコアについても教えてください
    　Q49 がんの術後合併症としてのVTEの頻度，意義とハイリスクな患者像を教えてください
    　Q50 VTEの診断について，どのような症例にどのような検査を施行したらよいのか教えてください
    　Q51 免疫調節薬（サリドマイド，レナリドミド）の作用機序，
    　　　　適応となるがんとその心毒性について教えてください
    　Q52 VTEを合併しやすい抗がん剤について教えてください
    　Q53 がん患者のVTEそして肺動脈血栓塞栓症の急性期治療について教えてください
    　Q54 がん患者のVTEの慢性期治療について教えてください：ワルファリンvs低分子ヘパリン
    　Q55 がん患者のVTEに対してDOACの有効性は証明されているのでしょうか？
    　Q56 がん患者のVTEに対して抗凝固療法はいつまで続けたらよいのでしょうか？
    　　　　そしてどのようにフォローしていけばよいのでしょうか？
    　Q57 特にVTE再発リスクの高い病態について教えてください

    Part ４　心臓とがん
    　Q58 原発性心臓腫瘍とその診断，治療について教えてください
    　Q59 転移性心臓腫瘍はどのようなものが多いのか教えてください
    　Q60 がん性心膜炎，心タンポナーデの対策について教えてください
    　Q61 ALアミロイドーシスの心不全について病態と治療を教えてください

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 腫瘍循環器とは

P.3 掲載の参考文献
1) Minami, M et al : Cardiovascular side-effects of modern cancer therapy. Circ J 74 : 1779-1786, 2010
PubMed
2) Suter, TM et al : Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25 : 3859-3865, 2007
 
3) Patnaik, JL et al : Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer. Breast Cancer Res 13 : R64, 2011
PubMed
4) Armstrong, GT et al : Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32 : 1218-1227, 2014
PubMed
P.5 掲載の参考文献
1) Yeh, ET et al : Cardiovascular complications of cancer therapy : Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 : 2231-2247, 2009
PubMed
2) 向井幹夫 : 【がん治療の進歩に伴う新しい分野の展開】 腫瘍循環器外来とはonco-cardiology. 成人病 55 : 7-9, 2015
 
3) Snipelisky, D et al : How to develop a cardio-oncology clinic. Heart Fail Clin 13 : 347-359, 2017
PubMed
4) 向井幹夫 : がん診療における腫瘍循環器外来の役割. 日本医事新報 4631 : 48-49, 2013
Medical*Online
5) Moslehi, JJ : Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 : 1457-1467, 2016
PubMed
P.7 掲載の参考文献
1) Dimopoulos, MA et al : Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375 : 1319-1331, 2016
PubMed
P.9 掲載の参考文献
1) Swain, SM et al : Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer 97 : 2869-2879, 2003
PubMed
2) Russo, G et al : Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. J Cardiovasc Med (Hagerstown) 15 : 141-146, 2014
PubMed
3) Udagawa, C et al : Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. Cancer Sci 109 : 446-452, 2018
PubMed
4) Ansari, D et al : Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr 4 : 325-335, 2015
PubMed
5) Kappelmayer, J et al : The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. Biomed Res Int 2017 : 6138145, 2017
PubMed
6) Varki, A : Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood 110 : 1723-1729, 2007
 
P.11 掲載の参考文献
1) Zagar, TM et al : Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 13 : 172-184, 2016
PubMed
2) Darby, SC et al : Radiation-related heart disease : current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76 : 656-665, 2010
PubMed
3) Darby, SC et al : Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 : 987-998, 2013
PubMed
4) Hojris, I et al : Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy : analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 354 : 1425-1430, 1999
PubMed
5) Darby, SC et al : Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer : prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6 : 557-565, 2005
PubMed
6) Gujral, DM et al : Radiation-induced carotid artery atherosclerosis. Radiother Oncol 110 : 31-38, 2014
PubMed
P.13 掲載の参考文献
1) Yeh, ET et al : Cardiovascular complication of cancer therapy. Incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 53 : 2231-2247, 2009
PubMed
2) Barac, A et al : Cardiovascular health of patients with cancer and cancer survivors : A roadmap to the next level. J Am Coll Cardiol 65 : 2739-2746, 2015
 
3) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
4) Plana, JC et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014
PubMed
5) 佐瀬一洋 : がん治療に関連する心疾患からがんサバイバーを守る-重要性を増すCardio-Oncology-. 新薬と臨床 66 : 81-88, 2017
 
P.15 掲載の参考文献
1) Committee on cancer survivorship, institute of medicine. From Cancer Patient to Cancer Survivor : Lost in Transition, Hewitt, M et al eds, The National Academies Press, Washington D. C., 2006
 
2) American Cancer Society. Facts & Figures http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2016-2017.pdf (2018年2月閲覧)
 
3) Szalda, D et al : 11. Cardiac toxic chemotherapy and cancer survivorship. Cardio-Oncology. The Clinical Overlap of Cancer and Heart Disease, Kimmick, GG et al eds, Springer International, Switzerland, 2016
 
4) Shelburne, N et al : Cancer Treatment-related cardiotoxicity : current state of knowledge and future research priorities. J Natl Cancer Inst 106 : dju232, 2014
PubMed
5) 佐瀬一洋 : がん治療に関連する心疾患からがんサバイバーを守る-重要性を増すCardio-Oncology-. 新薬と臨牀 66 : 813-820, 2017
Medical*Online
P.17 掲載の参考文献
1) van der Pal, HJ et al : High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30 : 1429-1437, 2012
PubMed
2) Lipshultz, SE et al : Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 : 1738-1743, 1995
PubMed
3) Felker, GM et al : Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 : 1077-1084, 2000
PubMed
4) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
5) Gudmundsdottir, T et al : Cardiovascular disease in adult life after childhood cancer in Scandinavia : A population-based cohort study of 32,308 one-year survivors. Int J Cancer 137 : 1176-1186, 2015
PubMed
P.19 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
2) 政府統計の総合窓口e-Stat : https://www.e-stat.go.jp/SG1/estat/eStatTopPortal.do (2017年12月閲覧)
 
3) Pinder, MC et al : Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25 : 3808-3815, 2007
PubMed
4) Swain, SM et al : Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials. Cancer 97 : 2869-2879, 2003
PubMed
5) Aapro, M et al : Anthracycline cardiotoxicity in the elderly cancer patient : a SIOG expert position paper. Ann Oncol 22 : 257-267, 2011
 
P.22 掲載の参考文献
1) Barac, A et al : Cardiovascular health of patients with cancer and cancer survivors : A roadmap to the next level. J Am Coll Cardiol 65 : 2739-2746, 2015
 
2) Yeh, ET : Onco-cardiology : the time has come. Tex Heart Inst J 38 : 246-247, 2011
PubMed
3) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
4) Lenihan, DJ et al : Cardio-oncology training : A proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty. J Card Fail 22 : 465-471, 2016
 

Part 2 がん治療に伴う心毒性

P.26 掲載の参考文献
1) 向井幹夫 : がんと心疾患-腫瘍循環器学 (Onco-Cardiology) とは. 循環器疾患最新の治療 2018-2019, 永井良三監修, 伊藤浩ほか編集, 南江堂, 49-54, 2018
 
2) Barac, A et al : Cardiovascular health of patients with cancer and cancer survivors : a roadmap to the next level. J Am Coll Cardiol 65 : 2739-2746, 2015
 
3) Yeh, ET et al : Cardiovascular complication of cancer therapy. Incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 53 : 2231-2247, 2009
PubMed
4) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guideline : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J 37 : 2768-2801, 2016
 
5) Moslehi, JJ : Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 : 1457-1467, 2016
PubMed
6) Mehta, LS et al : Cardiovascular disease and breast cancer where these entities intersect. Circulation 137, 2018 (DOI : 10.1161/CIR.0000000000000556)
 
P.29 掲載の参考文献
1) Plana, JC et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014
PubMed
2) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. Eur Heart J 37 : 2768-2801, 2016
PubMed
3) Ewer, MS et al : Type II chemotherapy-related cardiac dysfunction : time to recognize a new entity. J Clin Oncol 23 : 2900-2902, 2005
PubMed
4) Cardinale, D et al : Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 : 1981-1988, 2015
PubMed
5) Guarneri, V et al : Long-term cardiac tolerability of trastuzumab in metastatic breast cancer : the MD Anderson Cancer Center experience. J Clin Oncol 24 : 4107-4115, 2006
 
6) Johnson, DB et al : Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 : 1749-1755, 2016
PubMed
7) Sawaya, H et al : Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5 : 596-603, 2012
PubMed
P.31 掲載の参考文献
1) Escudier, M et al : Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136 : 2085-2087, 2017
PubMed
2) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
3) Lyman, GH et al : American Society of Clinical Oncology guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 : 5490-5505, 2007
 
P.33 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
P.35 掲載の参考文献
1) Plana, JC et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 : 911-939, 2014
PubMed
2) Hensley, ML et al : American Society of Clinical Oncology 2008 clinical practice guideline update : use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 : 127-145, 2009
 
3) Cardinale, D et al : Anthracycline-induced cardiomyopathy : clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55 : 213-220, 2010
PubMed
4) Negishi, T et al : Echocardiographic evaluation of cardiac function after cancer chemotherapy. J Echocardiogr 2017 published online (DOI 10.1007/s12574-017-0344-6)
 
5) Negishi, K et al : Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15 : 324-331, 2014
PubMed
P.37 掲載の参考文献
1) 大岩加奈ほか : R-CHOP療法が有効であった寒冷凝集素症に合併したB細胞リンパ腫. 日本輸血細胞治療学会誌 63 : 607-613, 2017
Medical*Online
2) Zaitsu, R et al : Phase I study of combination therapy with pegylated liposomal doxorubicin and gemcitabine in Japanese patients with recurrent ovarian cancer. J Tokyo Med Univ 75 : 78-83, 2017
 
3) 齋藤渉ほか : 妊娠中に急速増大した乳癌に対して手術・化学療法を施行した1例. 現代産婦人科 66 : S39-40, 2017
Medical*Online
4) 緒方憲太郎ほか : アントラサイクリン系抗腫瘍性抗生物質. 医学のあゆみ 215 : 311-316, 2005
Medical*Online
5) 庄野裕志 : シーリーグ : 殺細胞性抗がん剤 チーム アンチビオ 抗がん性抗生物質. プロフェッショナルがんナーシング 7 : 130-134, 2017
 
P.39 掲載の参考文献
1) 清野精彦ほか : 抗悪性腫瘍薬による心筋症. 日循専門医誌 4 : 337-342, 1996
 
2) 清野精彦 : 癌化学療法による心毒性-Anthracycline およびTrastuzumab心毒性について. 心臓 46 : 322-329, 2014
 
3) 青野真由美ほか : がん化学療法における心筋障害の病態と対策-アントラサイクリン心筋症など. 呼吸と循環 64 : 849-857, 2016
 
4) Hensley, ML et al : American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 : 3333-3356, 1999
 
5) Cardinale, D et al : Anthracycline-induced cardiomyopathy : clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55 : 213-220, 2010
PubMed
P.41 掲載の参考文献
1) Takemura, G et al : Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49 : 330-352, 2007
PubMed
2) Zhang, S et al : Identification of molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18 : 1639-1642, 2012
PubMed
3) Li, DL et al : Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133 : 1668-1687, 2016
PubMed
4) Hanna, AD et al : Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Mol Pharm 86 : 438-449, 2014
 
5) Huang, CH et al : Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 121 : 675-683, 2010
 
P.43 掲載の参考文献
1) Coussens, L et al : Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230 : 1132-1139, 1985
PubMed
2) Slamon, DJ et al : Human breast cancer : correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 : 177-182, 1987
PubMed
3) Lee, KF et al : Requirement for neuregulin receptor erbB2 in neural and cardiac development. Science 378 : 394-398, 1995
 
4) Crone, SA et al : ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8 : 459-465, 2002
PubMed
5) Slamon, DJ et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783-792, 2001
 
P.45 掲載の参考文献
1) Moslehi, JJ : Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 : 1457-1467, 2016
PubMed
2) Slamon, DJ et al : Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 : 783-792, 2001
 
3) Dang, C et al : Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2 : 29-36, 2016
PubMed
4) Slamon, D et al : Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 : 1273-1283, 2011
PubMed
P.47 掲載の参考文献
1) Folkman, J : Tumor angiogenesis : therapeutic implications. N Engl J Med 285 : 1182-1186, 1971
PubMed
2) Ferrara, N et al : Angiogenesis as a therapeutic target. Nature 438 : 967-974, 2005
PubMed
3) Shibuya, M et al : Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 : 549-560, 2006
PubMed
4) Jain, RK et al : Normalizing tumor vasculature with anti-angiogenic therapy : a new paradigm for combination therapy. Nat Med 7 : 987-989, 2001
PubMed
P.49 掲載の参考文献
1) 「アバスチン特定使用成績調査集計結果」, 中外製薬, 2017
 
2) Choueiri, TK et al : Congestive heart failure risk in patients with breast cancer treated with bevasizumab. J Clin Oncol 29 : 632-638, 2011
 
P.52 掲載の参考文献
1) Faivre, S et al : New Pardigms in anticancertherapy : targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33 : 407-420, 2006
 
2) Huang, L et al : Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 5 : 390-401, 2015
PubMed
3) Mok, TS et al : Gefinitib or carboplatin-paclitaxel in pulmonary adenocartinoma. N Engl J Med 361 : 947-957, 2009
PubMed
P.55 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatment and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
2) Greineder, CF et al : Heart failure associated with sunitinib : lessons learned from animal models. Curr Hypertens Rep 13 : 436-441, 2011
PubMed
3) Dahlen, T et al : Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia : A population-based cohort study. Ann Intern Med 165 : 161-166, 2016
PubMed
4) Force, T et al : Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7 : 332-344, 2007
PubMed
P.57 掲載の参考文献
1) Richardson, PG et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005
 
2) Stewart, AK et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015
PubMed
3) Moreau, P et al : Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 : 1621-1634, 2016
PubMed
4) Laubach, JP et al : A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma : towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol 178 : 547-560, 2017
PubMed
5) Takamatsu, H et al : Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol 91 : 903-906, 2010
 
P.59 掲載の参考文献
1) 日本臨床腫瘍学会編 : がん免疫療法ガイドライン, 金原出版, 東京, 2016
 
2) 向井幹夫 : 腫瘍循環器 (Onco-Cardiology) とは. 呼吸と循環 64 : 839-840, 2016
 
3) 鈴木重明 : どのように "irAE" 重症筋無力症を管理するか?. 医学のあゆみ 261 : 1142-1146, 2017
Medical*Online
4) Johnson, DB et al : Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 : 1749-1755, 2016
PubMed
5) Tajiri, K et al : Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol 48 : 7-12, 2018
PubMed
P.61 掲載の参考文献
1) Jaworski, C et al : Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61 : 2319-2328, 2013
PubMed
2) van Nimwegen, FA et al : Risk of heart failure in survivors of Hodgkin lymphoma : effects of cardiac exposure to radiation and anthracyclines. Blood 129 : 2257-2265, 2017
PubMed
3) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
4) Lancellotti, P et al : Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14 : 721-740, 2013
PubMed
5) Wethal, T et al : Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer 101 : 575-581, 2009
PubMed
P.64 掲載の参考文献
1) Plana, JC et al : Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15 : 1063-1093, 2014
PubMed
2) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. Eur J Heart Fail 19 : 9-42, 2017
 
3) Curigliano, G et al : Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy : ESMO Clinical Practice Guidelines. Ann Oncol 23 : vii 155-vii 166, 2012
 
4) Cardinale, D et al : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 : 2474-2481, 2006
PubMed
P.67 掲載の参考文献
1) Lipshultz, SE et al : Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia : long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11 : 950-961, 2010
PubMed
2) Cardinale, D et al : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 : 2474-2481, 2006
PubMed
3) Kalay, N et al : Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 : 2258-2262, 2006
PubMed
4) Seicean, S et al : Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy : an observational clinical cohort study. J Am Coll Cardiol 60 : 2384-2390, 2012
 
5) Kalam, K et al : Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy : a systematic review and meta-analysis. Eur J Cancer 49 : 2900-2909, 2013
PubMed
P.70 掲載の参考文献
1) Abdel-Qadir, H et al : Prevention, detection, and management of chemotherapy-related cardiac dysfunction. Can J Cardiol 32 : 891-899, 2016
PubMed
2) Seino, Y et al : Expanding the role of cardiac biomarkers-natriuretic peptides and troponins-further in pre-Stage A. Hypertens Res 38 : 11-12, 2015
 
3) Fallah-Rad, N et al : The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57 : 2263-2270, 2011
PubMed
4) Hensley, ML et al : American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17 : 3333-3355, 1999
 
5) Cardinale, D et al : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 : 2474-2481, 2006
PubMed
P.73 掲載の参考文献
1) Herrmann, J et al : Vascular toxicities of cancer therapies : the old and the new-an evolving avenue. Circulation 133 : 1272-1289, 2016
PubMed
2) Cameron, AC et al : Vascular complications of cancer chemotherapy. Can J Cardiol 32 : 852-862, 2016
PubMed
P.75 掲載の参考文献
1) de Forni, M et al : Cardiotoxicity of high-dose continuous infusion fluorouracil : A prospective clinical study. J Clin Oncol 10 : 1795-1801, 1992
PubMed
2) Jensen, SA et al : Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58 : 487-493, 2006
 
3) Nuver, J et al : Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23 : 9130-9137, 2005
PubMed
4) Vaklavas, C et al : Anti-vascular endothelial growth factor therapies and cardiovascular toxicity : What are the important clinical markers to target? Oncologist 15 : 130-141, 2010
PubMed
5) Kamba, T et al : Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 : 1788-1795, 2007
PubMed
P.78 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
2) アバスチン適正使用検討委員会監修 : 適正使用ガイド, アバスチン点滴静注用 100mg/4mL, 中外製薬 https://chugai-pharm.jp/hc/ss/pr/drug/ava_via0100/guide/cl_001.html (2018年1月閲覧)
 
3) de Jesus-Gonzalez, N et al : Management of antiangiogenic therapy-induced hypertension. Hypertension 60 : 607-615, 2012
PubMed
P.81 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. Eur Heart J 37 : 2768-2801, 2016
PubMed
2) 室原豊明 : 分子標的薬による心血管障害. 心臓 49 : 812-815, 2017
Medical*Online
3) 三好千春ほか : 腫瘍の増殖過程における血管新生. 日本バイオレオロジー学会誌 15 : 146-155, 2001
 
4) 倉智博久 : 中高年女性の健康ケア. 日産婦誌 54 : 246-251, 2002
 
5) 緩和医療ガイドライン作成委員会 : がん疼痛の薬物療法に関するガイドライン, 2版, 金原出版, 東京, 2014
 
P.83 掲載の参考文献
1) 日本高血圧学会 : 高血圧治療ガイドライン 2014, ライフサイエンス出版, 東京, 2014
 
2) Maitland, ML et al : Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102 : 596-604, 2010
PubMed
3) Suter, TM et al : Cancer drugs and the heart : importance and management. Eur Heart J 34 : 1102-1111, 2013
PubMed
4) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. Eur Heart J 37 : 2768-2801, 2016
PubMed
P.85 掲載の参考文献
1) Eremina, V et al : VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 : 1129-1136, 2008
PubMed
2) Markowitz, GS et al : Treatment with IFN-α, -β, or-γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5 : 607-615, 2010
 
3) Yao, X et al : Cisplatin nephrotoxicity : a review. Am J Med Sci 334 : 115-124, 2007
PubMed
4) 薬剤性腎障害の診療ガイドライン作成委員会 : 薬剤性腎障害診療ガイドライン 2016. 日腎会誌 58 : 477-555, 2016
 
5) がん薬物療法時の診療ガイドライン作成委員会 : がん薬物療法時の診療ガイドライン 2016. 日腎会誌 58 : 985-1051, 2016
 
P.87 掲載の参考文献
1) Weatherald, J et al : Long-term outcomes of dasatinib-induced pulmonary arterial hypertension : A population-based study. Eur Respir J 50, 2017
PubMed
2) Mateos, MV et al : Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma : Results of a multicenter phase 1/2 study. Blood 108 : 2165-2172, 2006
PubMed
3) Siegel, D et al : Integrated safety profile of single-agent carfilzomib : Experience from 526 patients enrolled in 4 phase ii clinical studies. Haematologica 98 : 1753-1761, 2013
PubMed
4) Ranchoux, B et al : Chemotherapy-induced pulmonary hypertension : Role of alkylating agents. Am J Pathol 185 : 356-371, 2015
PubMed
P.89 掲載の参考文献
1) Carol, C et al : Comprehensive review on cardio-oncology : Role of multimodality imaging. J Nucl Cardiol 24 : 906-935, 2017
 
2) Jose, Z et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur J Heart Fail 19 : 9-42, 2017
 
3) Rosa, GM et al : Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest 46 : 264-284, 2016
PubMed
4) Carrie, G et al : Cardio-oncology an update on cardiotoxicity of cancer-related treatment. Circ Res 118 : 1008-1020, 2016
PubMed
5) Tajiri, K et al : Cardio-oncology : a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol 47 : 678-682, 2017
PubMed
P.91 掲載の参考文献
1) Ganatra, S et al : Re-evaluating the safety of drug-eluting stents in cancer patients. J Am Coll Cardiol Intv 10 : 2334-2337, 2017
 
2) 日本循環器学会 : 循環器病ガイドラインシリーズ : 非心臓手術における合併心疾患の評価と管理に関するガイドライン (2014年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2014_kyo_h.pdf (2018年1月閲覧)
 
P.94 掲載の参考文献
1) Groarke, J et al : Cardiovascular complications of radiation therapy for thoracic malignancies : the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 35 : 612-623, 2014
PubMed
2) Darby, S et al : Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 : 987-998, 2013
PubMed
3) Lancellotti, P et al : Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults : a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 14 : 721-740, 2013
PubMed
4) Wu, W et al : Long-term survival of patients with radiation heart disease undergoing cardiac surgery : a cohort study. Circulation 127 : 1476-1484, 2013
PubMed
5) Schomig, K et al : Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv 70 : 359-365, 2007
PubMed
P.97 掲載の参考文献
1) Tamargo, J et al : Cancer chemotherapy and cardiac arrhythmias : a review. Drug Saf 38 : 129-152, 2015
PubMed
2) Yeh, ET et al : Cardiovascular complications of cancer therapy : incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 : 2231-2247, 2009
PubMed
3) Barlogie, B et al : Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 : 1021-1030, 2006
PubMed
P.99 掲載の参考文献
1) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines. Eur Heart J 37 : 2768-2801, 2016
PubMed
2) Chang, HM et al : Cardiovascular complications of cancer therapy. J Am Coll Cardiol 20 : 2552-2565, 2017
PubMed
P.102 掲載の参考文献
1) Farmakis, D et al : Insights into onco-cardiology : atrial fibrillation in cancer. J Am Coll Cardiol 63 : 945-953, 2014
 
2) 庄司正昭 : がん診療における不整脈-心房細動, QT時間延長を中心に. 呼吸と循環 64 : 875-880, 2016
 
3) Hu, YF et al : Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 165 : 355-357, 2013
PubMed
4) Conen, D et al : Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol 1 : 389-396, 2016
PubMed
5) Erichsen, R et al : Colorectal cancer and risk of atrial fibrillation and flutter : a population-based case-control study. Intern Emerg Med 7 : 431-438, 2012
PubMed
P.104 掲載の参考文献
1) Mery, B et al : Atrial fibrillation in cancer patients : Hindsight, insight and foresight. Int J Cardiol 240 : 196-202, 2017
PubMed
2) Heidbuchel, H et al : Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. EP Europace 17 : 1467-1507, 2015
PubMed
3) Zamorano, JL et al : 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines : The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
4) Farmakis, D et al : Insights into onco-cardiology : atrial fibrillation in cancer. J Am Coll Cardiol 63 : 945-953, 2014
 
5) Sueta, D et al : Letter by Sueta et al regarding article, "Urgent need to measure effects of direct oral anticoagulants". Circulation 134 : e496-e497, 2016
PubMed
6) De Caterina, R et al : New oral anticoagulants in atrial fibrillation and acute coronary syndromes : ESC Working Group on Thrombosis-Task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 59 : 1413-1425, 2012
 

Part 3 クローズアップされるがん関連血栓塞栓症

P.107 掲載の参考文献
1) Boccaccio, C et al : Genetic link between cancer and thrombosis. J Clin Oncol 27 : 4827-4833, 2009
PubMed
2) Boccaccio, C et al : The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 : 396-400, 2005
PubMed
3) Labelle, M et al : Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20 : 576-590, 2011
PubMed
4) Wang, R et al : Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468 : 829-833, 2010
PubMed
5) Demers, M et al : Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109 : 13076-13081, 2012
PubMed
P.109 掲載の参考文献
1) 春日雅人ほか : 糖尿病と癌に関する委員会報告. 糖尿病 56 : 374-390, 2013
 
2) Navi, BB et al : Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70 : 926-938, 2017
 
3) 向井幹夫 : がん治療における血栓塞栓症. 腫瘍循環器 (Onco-Cardiology) における診断と治療. 心臓 49 : 816-821, 2017
Medical*Online
4) Li, W et al : Vascular and metabolic implications of novel targeted cancer therapies : focus on kinase inhibitors. J Am Coll Cardiol 66 : 1160-1178, 2015
PubMed
P.111 掲載の参考文献
1) Timp, JF et al : Epidemiology of cancer-associated venous thrombosis. Blood 122 : 1712-1723, 2013
PubMed
2) Heit, JA et al : Risk factors for deep vein thrombosis and pulmonary embolism : a population-based case-control study. Arch Intern Med 160 : 809-815, 2000
PubMed
3) Nakamura, M et al : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014
PubMed
4) Zamorano, JL et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 37 : 2768-2801, 2016
PubMed
5) Varki, A : Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood 110 : 1723-1729, 2007
 
P.114 掲載の参考文献
1) Khorana, AA et al : Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 : 4902-4907, 2008
PubMed
2) Gerotziafas, GT et al : A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer : The prospective COMPASS-cancer-associated thrombosis study. Oncologist 22 : 1222-1231, 2017
PubMed
P.117 掲載の参考文献
1) Sakon M, et al : Incidence of venous thromboembolism following major abdominal surgery : a multi-center, prospective epidemiological study in Japan. J Thromb Haemost 4 : 581-586, 2006
PubMed
2) Kawaguchi R, et al : Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer. J Gynecol Oncol 23 : 98-102, 2012
PubMed
3) Agnelli G, et al : A Clinical outcome-based prospective study on venous thromboembolism after cancer surgery : the @ RISTOS project. Ann Surg 243 : 89-95, 2006
PubMed
4) White RH, et al : Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 90 : 446-455, 2003
 
5) Falanga A, et al : Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25 : 173-182, 1999
 
P.119 掲載の参考文献
1) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) : 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf (2018年2月閲覧)
 
2) Wells, PS et al : Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349 : 1227-1235, 2003
PubMed
3) Bates, SM et al : Diagnosis of DVT : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 : e351S-e418S, 2012
PubMed
4) Konstantinides, SV et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 : 3033-3069, 2014
PubMed
5) Le Gal, G et al : Prediction of pulmonary embolism in the emergency department : the revised Geneva score. Ann Intern Med 144 : 165-171, 2006
PubMed
P.122 掲載の参考文献
1) Quach, H et al : Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24 : 22-32, 2010
PubMed
2) Fischer, ES et al : Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512 : 49-53, 2014
PubMed
3) Stewart, AK : Medicine. How thalidomide works against cancer. Science 343 : 256-257, 2014
PubMed
4) Palumbo, A et al : Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22 : 414-423, 2008
PubMed
5) 赤司浩一総監修 : IMiDs基礎と臨床 2015, メディカルレビュー社, 東京, 2015
 
P.124 掲載の参考文献
1) Khorana, AA et al : Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the united states. Cancer 119 : 648-655, 2013
PubMed
2) Swystun, LL et al : Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 9 : 2313-2321, 2011
PubMed
3) Li, W et al : Vascular and metabolic implications of novel targeted cancer therapies : focus on kinase inhibitors. J Am Coll Cardiol 66 : 1160-1178, 2015
PubMed
4) Gottlieb, RA et al : Cardio-Oncology : Principles, Prevention and Management, Academic Press, Elsevier, 2017
 
5) Zangari, M et al : Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide : implications for therapy. Blood 100 : 1168-1171, 2002
PubMed
P.127 掲載の参考文献
1) Nakamura, M et al. : Current venous thromboembolism management and outcomes in Japan. Circ J 78 : 708-717, 2014
PubMed
2) Khorana, AA : Venous thromboembolism and prognosis in cancer. Thrombo Res 125 : 490-493, 2010
 
3) Konstantinides, SV et al : 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35 : 3033-3069, 69a-69k, 2014
 
4) Roskob, GE et al : Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2017 [Epub ahead of print]
 
P.129 掲載の参考文献
1) Lee, AY et al : Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 : 146-153, 2003
PubMed
2) Meyer, G et al : Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer : a randomized controlled study. Arch Intern Med 162 : 1729-1735, 2002
 
3) Lee, AYY et al : Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer : A randomized clinical trial. JAMA 314 : 677-686, 2015
 
4) Posch, F et al : Treatment of venous thromboembolism in patients with cancer : A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 136 : 582-589, 2015
 
5) Francis, CW et al : Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months : the DALTECAN Study. J Thromb Haemost 13 : 1028-1035, 2015
PubMed
P.131 掲載の参考文献
1) Raskob, GE et al : Edoxaban for venous thromboembolism in patients with cancer : results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3 : e379-e387, 2016
PubMed
2) Raskob, GE et al : Edoxaban for the treatment of cancer associated venous thromboembolism. N Engl J Med 2017 [Epub ahead of print]
 
P.133 掲載の参考文献
1) Raskob, GE et al : Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2017 [Epub ahead of primt]
 
2) Prandoni, P et al : Recurrent renous thromboembolism and bleeding complicatious during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 : 3484-3488, 2002.
 
3) Kearon, C et al : Amtithrombotic therapy for VTE disease : CHEST guideline and expert panel report. Chest 149 : 315-352, 2016
 
P.135 掲載の参考文献
1) Bauersachs, R et al : Overview of current evidence on the impact of the initial high dose of the direct factor Xa inhibitor rivaroxaban on thrombus resolution in the treatment of venous thromboembolism. Int Heart J 58 : 6-15, 2017
PubMed
2) Prandoni, P et al : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 : 3484-3488, 2002
PubMed
3) Ay, C et al : Cancer-associated venous thromboembolism : Burden, mechanisms, and management. Thromb Haemost 117 : 219-230, 2017
PubMed
4) Varki, A : Trousseau's syndrome : Multiple definitions and multiple mechanisms. Blood 110 : 1723-1729, 2007
 
5) Mandala, M et al : Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy : A prospective trial. Ann Oncol 21 : 871-876, 2010
PubMed

Part 4 心臓とがん

P.139 掲載の参考文献
1) Reynen, K : Frequency of primary tumors of the heart. Am J Cardiol 77 : 107, 1996
PubMed
2) Oliveira, GH et al : Characteristics and survival of malignant cardiac tumors : A 40-year analysis of > 500 patients. Circulation 132 : 2395-2402, 2015
PubMed
3) Silverman, NA : Primary cardiac tumors. Ann Surg 191 : 127-138, 1980
PubMed
4) Higo, T et al : Intracardiac echocardiography-guided cardiac tumor biopsy. Circ J 73 : 381-383, 2009
PubMed
5) Pinede, L et al : Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 80 : 159-172, 2001
PubMed
P.141 掲載の参考文献
1) Butany, J et al : A 30-year analysis of cardiac neoplasms at autopsy. Can J Cardiol 21 : 675-680, 2005
PubMed
2) Lam, KY et al : Tumors of the heart A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med 117 : 1027-1031, 1993
 
3) Amano, J et al : Clinical classification of cardiovascular tumors and tumor-like lesions, and it's incidences. Gen Thorac Cardiovasc Surg 61 : 435-447, 2013
 
4) Silvestri, F et al : Metastases of the heart and pericardium. G Ital Cardiol 27 : 1252-1255, 1997
PubMed
5) Klatt, EC et al : Cardiac metastasis. Cancer 65 : 1456-1459, 1990
 
P.144 掲載の参考文献
1) Adler, Y et al : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases : The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by : The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 : 2921-2964, 2015
 
2) Klatt, EC et al : Cardiac metastases. Cancer 65 : 1456-1459, 1990
PubMed
3) Fitch, MT et al : Videos in clinical medicine. Emergency pericardiocentesis. N Engl J Med 366 : e17, 2012
PubMed
4) 大倉裕二 : Oncologic emergencyとしての心外膜炎疾患 (心タンポナーデ). 呼吸と循環 64 : 893-898, 2016
 
5) Virk, SA et al : Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 101 : 1619-1626, 2015
PubMed
P.147 掲載の参考文献
1) Bradwell, AR et al : Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47 : 673-680, 2001
PubMed
2) Dittrich, T et al : AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 130 : 632-642, 2017
PubMed
3) Imperlini, E et al : Proteotoxicity in cardiac amyloidosis : amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep 7 : 15661, 2017
PubMed
4) Mikhael, JR et al : Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119 : 4391-4394, 2012
PubMed
5) Palladini, G et al : A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126 : 612-615, 2015
PubMed

書評

最近チェックした商品履歴

Loading...